To include your compound in the COVID-19 Resource Center, submit it here.

Basal insulin peglispro: Phase III data

Top-line data from the 26-week, open-label, international Phase III IMAGINE-6 trial in 641 insulin-naive Type II diabetics inadequately controlled on >=2 oral antihyperglycemic medications showed that

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE